Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by TRACON Pharmaceuticals, Inc. TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform July 01, 2024 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients June 11, 2024 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update May 14, 2024 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 May 07, 2024 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces Reverse Stock Split April 08, 2024 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned April 03, 2024 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update March 05, 2024 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024 February 28, 2024 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial December 20, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment November 20, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 09, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023 October 31, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned September 18, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences September 05, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 14, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023 August 02, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma July 11, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial June 20, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference June 16, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma June 15, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference June 02, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting May 30, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update May 10, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023 May 03, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab April 25, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update March 08, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023 February 28, 2023 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023 December 27, 2022 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial December 14, 2022 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma November 21, 2022 From TRACON Pharmaceuticals, Inc. Via GlobeNewswire Tickers TCON Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.